alpha-Cypermethrin

CAS No. 67375-30-8

alpha-Cypermethrin( Fendana )

Catalog No. M20126 CAS No. 67375-30-8

α-Cypermethrin is a synthetic pyrethroid pesticide used in large-scale commercial agricultural applications.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    alpha-Cypermethrin
  • Note
    Research use only, not for human use.
  • Brief Description
    α-Cypermethrin is a synthetic pyrethroid pesticide used in large-scale commercial agricultural applications.
  • Description
    α-Cypermethrin is a synthetic pyrethroid pesticide used in large-scale commercial agricultural applications.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Fendana
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    67375-30-8
  • Formula Weight
    416.3
  • Molecular Formula
    C22H19Cl2NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 41.63 mg/mL (100 mM);Water: 5 mg/mL (12 mM)
  • SMILES
    CC1(C)C(\C=C(\Cl)Cl)C1C(=O)OC(C#N)c1cccc(Oc2ccccc2)c1
  • Chemical Name
    (SR)-alpha-Cyano-3-phenoxybenzyl (1RS3RS)-3-(22-dichlorovinyl)-22-dimethylcyclopropanecarboxylate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Saillenfait AM et al. Evaluation of the effects of α-cypermethrin on fetal rat testicular steroidogenesis. Reprod Toxicol. 2017 Sep;72:106-114.
molnova catalog
related products
  • trans-Benzylideneace...

    trans-4-Phenyl-3-buten-2-one is used in various synthetic preparations.

  • Rhodiosin

    Rhodiosin is a compound with antioxidant activity.

  • Examorelin

    Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?